Rautio J, Meanwell NA, Di L, Hageman MJ (tháng 8 năm 2018). “The expanding role of prodrugs in contemporary drug design and development”. Nature Reviews. Drug Discovery (bằng tiếng Anh). 17 (8): 559–587. doi:10.1038/nrd.2018.46. PMID29700501.
Malhotra B, Gandelman K, Sachse R, Wood N, Michel MC (2009). “The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine”. Current Medicinal Chemistry. 16 (33): 4481–9. doi:10.2174/092986709789712835. PMID19835561.
Stella VJ, Charman WN, Naringrekar VH (tháng 5 năm 1985). “Prodrugs. Do they have advantages in clinical practice?”. Drugs. 29 (5): 455–73. doi:10.2165/00003495-198529050-00002. PMID3891303.
Rautio J, Meanwell NA, Di L, Hageman MJ (tháng 8 năm 2018). “The expanding role of prodrugs in contemporary drug design and development”. Nature Reviews. Drug Discovery (bằng tiếng Anh). 17 (8): 559–587. doi:10.1038/nrd.2018.46. PMID29700501.
Malhotra B, Gandelman K, Sachse R, Wood N, Michel MC (2009). “The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine”. Current Medicinal Chemistry. 16 (33): 4481–9. doi:10.2174/092986709789712835. PMID19835561.
Stella VJ, Charman WN, Naringrekar VH (tháng 5 năm 1985). “Prodrugs. Do they have advantages in clinical practice?”. Drugs. 29 (5): 455–73. doi:10.2165/00003495-198529050-00002. PMID3891303.